Výsledky vyhledávání - "Mary Frances Mulcahy"

A single-arm, phase II study of autophagy modulation using hydroxychloroquine in addition to encorafenib and cetuximab or panitumumab in metastatic BRAF-mutated colorectal cancer refractory to standard therapy

Autor: Chetan Vakkalagadda, Sabeeha Mukit, Masha Kocherginsky, Sheetal Mehta Kircher, Aparna Kalyan, Mary Frances Mulcahy, Al Bowen Benson, Navdeep Chandel, Devalingam Mahalingam

Publikováno v: Journal of Clinical Oncology. 41:TPS262-TPS262

TPS262 Background: BRAF mutations drive 5-10% of colon cancers. BRAF + EGFR inhibition with encorafenib + cetuximab is standard second-line therapy, per the BEACON trial, but responses are short-lived. Autophagy induction is implicated as a mechanism

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::eaa926749ce6867dd35afd4a01d2848f
https://doi.org/10.1200/jco.2023.41.4_suppl.tps262

Zobrazit plný text záznamu

Real-world outcome analysis of patients with advanced gastric and gastroesophageal adenocarcinoma with HER2-low expression treated with first-line therapy

Autor: Mary Frances Mulcahy, Halla Nimeiri, Osama E. Rahma, Jonathan Wills, Kristian Del Rosario, Justin Lien, Raphael Pelossof, Talal Ahmed, Justin Guinney, Nike Beaubier, Filippo Pietrantonio, Yoshiaki Nakamura, Iker Huerga, Takayuki Yoshino

Publikováno v: Journal of Clinical Oncology. 41:326-326

326 Background: HER2-low tumors, defined as a score of 1+ on immunohistochemical (IHC) analysis or as an IHC score of 2+ and negative results on in situ hybridization (ISH), are not well characterized among gastric or gastroesophageal junction adenoc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b0d6a3774d2fdedd032e31a80c230a8d
https://doi.org/10.1200/jco.2023.41.4_suppl.326

Zobrazit plný text záznamu

A phase Ib/II study of sotorasib combined with chemotherapy for second-line treatment of KRAS p. G12C–mutated advanced pancreatic cancer

Autor: Devalingam Mahalingam, Michael Charles Burns, Aparna Kalyan, Sheetal Mehta Kircher, Masha Kocherginsky, Mary Frances Mulcahy, Al Bowen Benson

Publikováno v: Journal of Clinical Oncology. 40:TPS4194-TPS4194

TPS4194 Background: Kirsten rat sarcoma viral oncogene homolog( KRAS) p.G12C mutation is an oncogenic driver mutation in several solid tumors. Sotorasib is a specific, irreversible, small molecule inhibitor of KRASG12C that has demonstrated durable c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ad9092f848d365578e437dc38f251001
https://doi.org/10.1200/jco.2022.40.16_suppl.tps4194

Zobrazit plný text záznamu

Phase 2 study of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, with gemcitabine/nab-paclitaxel (GnP) in first-line advanced pancreatic ductal adenocarcinoma (PDAC)

Autor: Devalingam Mahalingam, Benedito A. Carneiro, Howard Safran, Steven Francis Powell, Andrew L. Coveler, Elizabeth J. Davis, Andres Cervantes, Vaibhav Sahai, Neeltje Steeghs, Marisol Huerta, Jordan Berlin, Mary Frances Mulcahy, Francis J. Giles, Ludimila Cavalcante, Anwaar Saeed

Publikováno v: Journal of Clinical Oncology. 40:578-578

578 Background: GSK-3β overexpression is associated with worse prognosis and chemotherapy resistance in PDAC. GSK-3β inhibition reverses chemotherapy-resistance by inhibiting chemotherapy-induced, ATR-mediated, DNA damage response. 9-ING-41 has sig

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8a3a0ca159d0e8f4951947961fdb8e47
https://doi.org/10.1200/jco.2022.40.4_suppl.578

Zobrazit plný text záznamu

A phase II study of FOLFOX combined with nab-paclitaxel (FOLFOX-A) in the treatment of metastatic or advanced unresectable gastric, gastroesophageal junction adenocarcinoma: Big Ten Cancer Research Consortium—BTCRC-GI15-015

Autor: Al Bowen Benson, Masha Kocherginsky, Pashtoon Murtaza Kasi, Nataliya Volodymyrivna Uboha, Emil Lou, Yolande Chen, Howard S. Hochster, Sheetal Mehta Kircher, Mary Frances Mulcahy

Publikováno v: Journal of Clinical Oncology. 40:283-283

283 Background: Doublet platinum or taxane-based therapies are the current standard backbone of treatment for advanced gastric/GEJ adenocarcinoma. Previously, anthracycline based triplets have been aborted due to lack of efficacy and toxicity. We hyp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9c9154c933a715266352994ec16a6ff5
https://doi.org/10.1200/jco.2022.40.4_suppl.283

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání